Event: ACTRIMS 2023

0:08:57

MS Milan 2023: Research Insights from Day Three

0:01:24

TSPO-PET imaging in MS clinical trials and treatment decisions

0:02:33

Predicting benign disease course in MS

0:01:00

How does tDCS work in MS?

0:04:03

Serum proteins associated with glial cell injury, MRI measures & neuropsychological outcomes in MS

0:03:41

Phenotyping the prodrome could lead to earlier recognition of MS

0:04:41

Interpretation of serum NfL depends on the selection of a reference population

0:02:16

Myelin abnormalities in the cervical spinal cord associated with clinical disability in MS subtypes

0:02:07

What is the latest progress in gene research in MS?

0:02:18

Quantitative spinal cord magnetic resonance imaging in MS: value & challenges

0:02:16

An update on transcranial direct current situation (tDCS) in patients with MS

0:01:43

Progressive MS: emerging treatments

0:05:54

Types of infection implicated in MS pathogenesis

0:01:01

Tailoring treatment in MS with new S1P receptor modulators

0:06:43

Sean Pittock, ECTRIMS 2022: Phase 3 CHAMPION-NMOSD trial results – Ravulizumab for AQP4-IgG NMOSD

0:02:53

Future studies on damaging pathways associated with MS progression & severity

0:21:05

MS Milan 2023: Research Insights from Day Two

0:05:27

CSF immune cell phenotyping & NfL to measure inflammatory activity and DMT response in MS

0:04:59

Serum biomarkers of brain atrophy in MS

0:01:13

Longitudinal studies to bring sNfL to MS clinical practice

0:04:55

The burden of psychiatric morbidity in the MS prodrome

0:04:02

SARS-CoV-2 infections may increase MS risk and risk of exacerbations

0:02:15

Role of oligodendrocytes in demyelination & remyelination in MS: future research

0:03:32

Blood biomarkers of disease activity in MS